Lirentelimab (AK002)

An investigational monoclonal antibody selectively targeting Siglec-8, an inhibitory receptor found on mast cells and eosinophils

Eosinophilic Gastrointestinal Diseases (EGIDs)

Phase 2 study met all prespecified primary and secondary endpoints, Phase 3 eosinophilic gastritis and/or eosinophilic duodenitis (EG/EoD) and Phase 2/3 eosinophilic esophagitis (EoE) studies initiated

Other Diseases

Clinical activity demonstrated in multiple mast cell and eosinophil driven diseases